Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an <i>In Situ</i> Inflammatory Immune Response

Kristina Berg Lorvik, Clara Hammarström, Marte Fauskanger, +5

Cancer Research

CD4+ T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs

Ole Audun Werner Haabeth, Marte Fauskanger, Melanie Manzke, +4

Cancer Research

Tumor Killing by CD4+ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity

Marte Fauskanger, Ole Audun Werner Haabeth, Frode Miltzow Skjeldal, +2

Frontiers in Immunology

Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models

Jo Waaler, Line Mygland, Anders Tveita, +15

Communications Biology

Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules

Tor Kristian Andersen, Peter C. Huszthy, Ramakrishna Prabhu Gopalakrishnan, +5

npj Vaccines

Tumors Escape CD4+ T-cell–Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens

Anders Tveita, Fredrik Schjesvold, Ole Audun Werner Haabeth, +2

Cancer Research

CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages

Ole Audun Werner Haabeth, Kjartan Hennig, Marte Fauskanger, +3

Blood Advances

Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display

Anders Tveita, Marte Fauskanger, Bjarne Bogen, +1

Oncotarget